As previously reported, BofA analyst Alexandria Hammond initiated coverage of Madrigal Pharmaceuticals with an Underperform rating and $150 price target. The commercial stage company has received the first FDA approval for fatty liver disease, also known as MASH, though investors have “largely moved past Rezdiffra’s best-case scenario FDA approval” and payer pushback given Rezdiffra’s $47,000 annual price tag could prompt a slow launch, perpetuating a “short the launch thesis” and providing further downside potential for shares, the analyst argues.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MDGL:
- Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
- Madrigal: Rezdiffra available in the U.S. for noncirrhotic NASH
- Madrigal Pharmaceuticals price target raised to $405 from $325 at Evercore ISI
- Madrigal Pharmaceuticals 750K share Spot Secondary priced at $260.00
- Madrigal Pharmaceuticals Announces Pricing of Upsized $600 Million Public Offering